NCT04179396View on ClinicalTrials.gov

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

November 25, 2021

Study Completion Date

January 18, 2023

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

Rucaparib

Oral rucaparib will be administered twice daily

DRUG

Enzalutamide

"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."

DRUG

Abiraterone

Abiraterone will be administered once daily with prednisone

Trial Locations (3)

30318

Piedmont Cancer Institute, P.C., Atlanta

37209

Urology Associates, P.C., Nashville

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT04179396 - Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | Biotech Hunter | Biotech Hunter